{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:10:39Z","timestamp":1780445439716,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105154","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:14:37Z","timestamp":1769184877000},"page":"105154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic utility of circulating tumor DNA in classical hodgkin lymphoma: A systematic review and individual participant data bayesian meta-analysis"],"prefix":"10.1016","volume":"219","author":[{"given":"Amirhossein","family":"Shahsavand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Forghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Kharaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Samiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania A.","family":"Mekary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Aliasghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Fattahnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Daghaieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1347","authenticated-orcid":false,"given":"Tahereh","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Janbabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin's lymphoma--diagnosis and treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105154_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clml.2023.03.015","article-title":"Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States","volume":"23","author":"Winter","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-024-01125-4","article-title":"Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis","volume":"14","author":"Hannuksela","year":"2024","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105154_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1634\/theoncologist.2017-0541","article-title":"Long-Term Survival Rates of Patients with Stage III\u2013IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984\u20132013","volume":"23","author":"Li","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105154_bib6","article-title":"Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India","volume":"11","author":"Bhurani","year":"2021","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105154_bib7","article-title":"Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study","volume":"6","author":"Suwanban","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105154_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000460819","article-title":"Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia","volume":"40","author":"Shafi","year":"2017","journal-title":"Oncol. Res Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105154_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin's lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","article-title":"Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis","volume":"36","author":"Br\u00f6ckelmann","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hon.3131","article-title":"Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population","volume":"41","author":"N\u00fa\u00f1ez-Garc\u00eda","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105154_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/030089161209800510","article-title":"Long-term complications in Hodgkin's lymphoma survivors","volume":"98","author":"Kilickap","year":"2012","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/humupd\/dmr038","article-title":"Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review","volume":"18","author":"van Dorp","year":"2012","journal-title":"Hum. Reprod. Update"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105154_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1080\/10428194.2025.2476664","article-title":"Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins","volume":"66","author":"Haydon","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105154_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/jnci\/djae274","article-title":"Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma","volume":"117","author":"Roberti","year":"2025","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105154_bib16","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clml.2020.03.006","article-title":"Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment","volume":"20","author":"Laddaga","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/biomedinformatics3030035","article-title":"Using Machine Learning to Expand the Ann Arbor Staging System for Hodgkin and Non-Hodgkin Lymphoma","volume":"3","author":"Wang","year":"2023","journal-title":"BioMedInformatics [Internet]"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105154_bib18","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105154_bib19","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105154_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105154_bib21","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study","volume":"37","author":"Barrington","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105154_bib22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105154_bib23","first-page":"116","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105154_bib24","first-page":"1","article-title":"Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence","author":"Seshachalam","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105154_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/430679","article-title":"Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats","volume":"2011","author":"Andr\u00e9","year":"2011","journal-title":"Adv. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.semnuclmed.2022.10.006","article-title":"PET\/CT in Hodgkin Lymphoma: An Update","volume":"53","author":"Al-Ibraheem","year":"2023","journal-title":"Semin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105154_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040682","article-title":"Genomic Landscape of Hodgkin Lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105154_bib30","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00277-022-04949-x","article-title":"Circulating tumor DNA in Hodgkin lymphoma","volume":"101","author":"Maco","year":"2022","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105154_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105154_bib32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105154_bib34","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105154_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105154_bib36","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1080\/10428194.2022.2103808","article-title":"Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"63","author":"Taranto","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"7996","key":"10.1016\/j.critrevonc.2026.105154_bib37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105154_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma","author":"Heger","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105154_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105154_bib40","first-page":"1171","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med (N. Y. NY)"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105154_bib41","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105154_bib42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105154_bib43","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105154_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cell.2017.06.046","article-title":"IL-4R\u03b1 Inhibitor for Atopic Disease","volume":"170","author":"Chang","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib46","first-page":"CD012643","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"1","author":"Aldin","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"38","author":"Fuchs","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105154_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-Term Follow-Up of the Response-Adapted Intergroup EORTC\/LYSA\/FIL H10 Trial for Localized Hodgkin Lymphoma","volume":"42","author":"Federico","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105154_bib49","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"10450","key":"10.1016\/j.critrevonc.2026.105154_bib50","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105154_bib51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105154_bib52","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Br\u00f6ckelmann","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105154_bib53","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105154_bib54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2024-201877","article-title":"Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET\/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma","volume":"144","author":"Boegeholz","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105154_bib55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00428-019-02571-3","article-title":"IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing","volume":"474","author":"Deans","year":"2019","journal-title":"Virchows Arch."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105154_bib56","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105154_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2023.06.004","article-title":"Cell-free DNA in large B-cell lymphoma: MRD and beyond","volume":"60","author":"Sworder","year":"2023","journal-title":"Semin Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:24:38Z","timestamp":1770899078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"alternative-id":["S1040842826000417"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105154","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic utility of circulating tumor DNA in classical hodgkin lymphoma: A systematic review and individual participant data bayesian meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105154"}}